申请人:Eli Lilly and Company
公开号:US06670373B1
公开(公告)日:2003-12-30
The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
本发明涉及一种公式(I)的化合物,该化合物用于抑制由MRP1部分或全部赋予的耐药性肿瘤。